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Abstract
Glial cell line-derived neurotrophic factor (GDNF) is a neurotrophic factor for dopaminergic neurons with promising
therapeutic potential in Parkinson’s disease. A few association analyses between GDNF gene polymorphisms and psychiatric
disorders such as schizophrenia, attention deficit hyperactivity disorder and drug abuse have also been published but little
is known about any effects of these polymorphisms on mood characteristics such as anxiety and depression. Here we
present an association study between eight (rs1981844, rs3812047, rs3096140, rs2973041, rs2910702, rs1549250, rs2973050
and rs11111) GDNF single nucleotide polymorphisms (SNPs) and anxiety and depression scores measured by the Hospital
Anxiety and Depression Scale (HADS) on 708 Caucasian young adults with no psychiatric history. Results of the allele-wise
single marker association analyses provided significant effects of two single nucleotide polymorphisms on anxiety scores
following the Bonferroni correction for multiple testing (p = 0.00070 and p= 0.00138 for rs3812047 and rs3096140,
respectively), while no such result was obtained on depression scores. Haplotype analysis confirmed the role of these SNPs;
mean anxiety scores raised according to the number of risk alleles present in the haplotypes (p = 0.00029). A significant sex-
gene interaction was also observed since the effect of the rs3812047 A allele as a risk factor of anxiety was more
pronounced in males. In conclusion, this is the first demonstration of a significant association between the GDNF gene and
mood characteristics demonstrated by the association of two SNPs of the GDNF gene (rs3812047 and rs3096140) and
individual variability of anxiety using self-report data from a non-clinical sample.
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Introduction
Glial cell line-derived neurotrophic factor (GDNF), a member of
the TGFb superfamily that signals via cell-surface tyrosine kinase
receptors, is considered an essential neuroprotective ligand for
midbrain dopaminergic neurons [1] with promising clinical trials
in Parkinson’s disease [2]. As GDNF has also been shown to
promote the development and differentiation of dopaminergic
neurons [3] perturbed regulation of its expression has been
supposed to underlie several neuropsychiatric diseases such as
schizophrenia and depression via dysregulation of dopaminergic
neural circuitries and impaired synaptic plasticity [4,5].
Analysis of GDNF level changes in depressive disorders revealed
contradictory results. Both elevated [11,12] and reduced [13,14]
GDNF plasma concentrations have been reported in patients with
late-onset depression, major depression or bipolar disorder.
Antidepressants and electroconvulsive therapy seemed to enhance
rat hippocampal [15] and human plasma GDNF levels [16,17]
possibly via altered epigenetic regulation of the GDNF promoter
[18]. On the other hand, a recent post mortem analysis of human
brain samples disclosed elevated GDNF protein levels in the
parietal cortex but not in limbic areas and basal ganglia of patients
with depressive disorder [19].
Recent genetic association studies on neurotrophic factors
investigated the brain-derived neurotrophic factor (BDNF) and
the neurotrophin-3 receptor gene demonstrating association with
depression [6], anxiety disorders [7,8] or attention deficit
hyperactivity disorder [9]. Evidence was also provided for an
interaction between dopaminergic (COMT) and neurotrophic
(BDNF) gene variants influencing dysfunctional beliefs such as
threat [10] which might be linked to anxiety. Interestingly, the
potential etiopathological involvement of GDNF has rarely been
addressed by genetic studies. A genome-wide linkage study has
first shed light on the GDNF as potential candidate gene in
schizophrenia [20], followed by contradictory results from case-
control association studies [21,22]. This issue has extensively been
investigated later by Williams and co-workers [23]. They analyzed
9 SNPs (single nucleotide polymorphisms) encompassing the entire
genetic locus as well as a poly-AGG repeat in the 39 untranslated
region, but neither of them proved to be significantly associated
with schizophrenia. No associations have been found between
GDNF SNPs and attention deficit hyperactivity disorder (ADHD)
either [24,25].
GDNF was also shown to have a protective effect against
methamphetamine induced dopamine depletion related neurotox-
icity [26]. In addition, a single nucleotide polymorphism (SNP) of
GDNF (rs2910704) has recently been associated with metham-
phetamine dependence in a Japanese population [27]. Since mood
disorders are often accompanied by drug abuse [28], and impaired
dopaminergic signaling is a well-known factor in the pathogenesis
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of depression, we raised the question whether GDNF gene variants
might be risk factors of depression or anxiety. To clarify this issue,
here we present an association analysis between eight SNPs of the
GDNF gene and mood characteristics assessed by the Hospital
Anxiety and Depression Scale (HADS) questionnaire using data
from 708 healthy Caucasians. To our best knowledge, this is the




Non related Caucasian (Hungarian) subjects participated on a
voluntary basis from several educational facilities. They were
recruited at the Institute of Psychology, Eo¨tvo¨s Lora´nd University.
The study protocol was designed in accordance with guidelines of
the Declaration of Helsinki, and was approved by the Scientific
and Research Ethics Committee of the Medical Research Council
(ETT TUKEB). The participants signed a written informed
consent, provided buccal samples and filled out the Hospital
Anxiety and Depression Scale (HADS). Selection criteria included
no past or present psychiatric history (based on self-report), age
between 18–35 years, valid GDNF SNP data for at least five of the
eight analyzed SNPs and valid self-report data for the HADS
subscales. A total of 837 independent samples were genotyped by
the Open Array system, of which 767 subjects were between 18–
35 years and 760 of them filled out the HADS self-report scale. All
of these 760 subjects provided answers for at least six out of seven
items in each HADS subscale, therefore valid scale data could be
calculated. 708 of them had 5 or more GDNF genotypes providing
the final study population. As a result, we analyzed data from 708
subjects (46.3% males, 53.7% females; mean age: 21.363.4 years).
The sample comprised of 169 university students from the Institute
of Psychology, Eotvos Lorand University, 217 college and
university students from two law enforcement institutions in the
Budapest area and 322 volunteers recruited on different occasions
popularizing our research. Anxiety and depression scores (see
Table S1 in File S1), as well as age and sex ratios (see Table 1)
were different in these subgroups. On the other hand, genotype
frequencies of GDNF SNPs were similar in the subgroups (see
Table S2 in File S1), therefore the total sample was used for
association analyses.
Phenotype measures
All subjects completed the Hungarian version [29] of the
Hospital Anxiety and Depression Scale (HADS). This self-report
tool was originally developed by Zigmond and Snaith [30]. The
questionnaire contains 14 intermixed items of two scales for
detecting levels of anxiety (7 items) and depression (7 items). Both
scales contain straightforward and reversed items to ensure
attentive responses. Items are scored from 0–3 based on the
releated response category (e.g. most of the time – not at all). The
final raw score of both scales range from 0–21, sum of the
appropiate items’ scores. In the paper describing the Hungarian
translation and validation of the HADS questionnaire [29] high
internal consistency and discriminating power was found based on
a sample of 715 Hungarian cancer patients. Concurrent validity of
the HADS depression and anxiety scales has been attested with the
Symptom List and the Beck Depression Scale. HADS anxiety
scores increased with the number of anxiety-related emotional
problems, such as ‘fears’, ‘nervousness’, and ‘worry’ and similarly
increased HADS depression scores were found in those reporting
‘depression’ and ‘sadness’. Correlation of the depression scale of
the HADS and the Beck Depression Scale (r = 0.81) also indicate
sufficient concurrent validity.
The SNP selection criteria
Single nucleotide polymorphisms (SNPs) with a minor allele
frequency (MAF) greater than 0.05 were selected from the Single
Nucleotide Polymorphism database of NCBI (dbSNP). The
pairwise tagging method using r2 threshold of 0.8 by Haploview
was used to determine tagging SNPs based on HapMap data to
obtain a proper coverage of the GDNF gene. SNPs with a
reference from previous association studies concerning neuropsy-
chiatric disorders were preferred.
Table 1. Anxiety and depression in the three subject groups.
Subject groups N Age Male/female
Psychology students 169 18–35 (20.3262.74) 16.6%/83.4%
Students in law
enforcement
217 18–35 (20.2762.08) 73.3%/26.3%
Other volunteers 322 18–35 (22.5763.96) 43.5%/56.5%
Total sample 708 18–35 (21.3363.39) 46.3%/53.7%
Note. Range, mean values and StDev are provided for age.
doi:10.1371/journal.pone.0080613.t001
Table 2. Genotype distribution of the studied GDNF
polymorphisms.
dbSNP No Genotype N % HWE* Call rate
rs1981844 GG 313 55.1 p = 0.537 80.2%
CG 224 39.4
CC 31 5.5
rs3812047 GG 542 76.6 p = 0.962 100,0%
GA 154 21.7
AA 12 1.7
rs3096140 TT 316 48.0 p = 0.928 92.9%
TC 283 43.0
CC 59 9.0
rs2973041 AA 488 70.6 p = 0.727 97.6%
AG 182 26.4
GG 21 3.0
rs2910702 AA 380 54.8 p = 0.911 98.0%
GA 270 38.9
GG 44 6.3
rs1549250 TT 235 33.5 p = 0.970 99.0%
TG 339 48.4
GG 127 18.1
rs2973050 CC 237 40.6 p = 0.340 82.3%
TC 282 48.4
TT 64 11.0
rs11111 AA 535 75.9 p = 0.321 99,6%
AG 153 21.7
GG 17 2.4
Note. * Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0080613.t002
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Sample preparation and SNP genotyping
Collection of buccal swabs and isolation of genomic DNA was
carried out as described in [24] with some modifications. Briefly,
swabs were incubated in 450 mL lysis solution containing 0.2 g/L
Proteinase K, 0.1 M NaCl, 0.5% SDS and 0.01 M Tris buffer,
pH =8 at 56uC overnight followed by RNase treatment at room
temperature. Proteins were removed with saturated NaCl (2:1
volume ratio). After the standard procedure of DNA precipita-
tion with isopropanol and ethanol, the pellet was resuspended in
100 mL of 5 mM Tris pH =8, 0.5 mM EDTA. Concentration of
double stranded DNA was measured by fluorometry applying an
intercalation assay (AccuBlue Broad Range dsDNA Quantifica-
tion Kit, Biotium, Hayward). The range of the DNA concen-
tration was 15–200 ng/mL, samples with lower than 15 ng/mL
were not used for the OpenArray analysis.
Genotypes were determined applying the TaqManH Open-
ArrayTM Genotyping System (Applied Biosystems, Forster City,
CA) based on sequence-specific, fluorescent TaqMan probes in
combination with a high-throughput PCR system using nanoliter-
scale sample volume and post-PCR (endpoint) detection. Geno-
typing platforms were obtained from the manufacturer as
immobilized target specific primers and fluorescent probes in a
low density array format. Reaction mixtures containing approx-
imately 100 ng DNA (range: 30–150 ng) and the 16master mix
(each deoxyribonucleoside triphosphate and the AmpliTaq Gold
DNA-polymerase, provided by the manufacturer) were prepared
on a 384-well sample plate and then loaded on the genotyping
plates by the OpenArrayTM Autoloader. PCR amplification was
performed in the GeneAmpH PCR System 9700 (Applied
Biosystems, Forster City, CA) following the manufacturer’s
instruction. Endpoint imaging of the allele specific FAM and
VIC fluorescent intensities was made by the OpenArrayTM NT
Imager. Raw data were evaluated by the TaqMan Genotyper v1.2
software.
2% of the DNA samples were repeatedly applied on the
OpenArray system, demonstrating a 98,2% reproducibility. In
addition, a subsample was re-genotyped for two SNPs (rs3812047,
rs3096140) were re-genotyped with a 7300 Real-Time PCR
System (Applied Biosystems, Foster City, CA) for quality control
also providing an increase in the call rate of these SNPs. Original
call rates of OpenArrayTM Genotyping System are presented in
Table S3 in File S1, while the call rates calculated for the final
study population is given in Table 2. As it can be seen in these
Tables, all the genotypes were in Hardy-Weinberg equilibrium.
Statistical Analysis
Statistical analyses were carried out using SPSS 20.0 for
Windows. Chi-square analysis was used to test reliability of the
measured genotype and allele frequencies. Lewontin’s D’ as well as
R2 values of linkage disequilibrium were determined using
HaploView 4.2 [31]. Haplotypes were determined by the Phase
program [32–34]. Independent-Samples t-test was used to assess
sex differences; relationship with age has been tested by correlation
analyses. One way analyses of covariance (ANCOVA) was used to
test genetic associations of the single and multiple marker analyses
in an allele-wise design. False positive results were ruled out by
Bonferroni correction for multiple testing. The corrected level of
significance was p,0.00313, as the nominal p (value 0.05) was
divided by the number of analyses performed (8 SNPs62 HADS
scales = 16). Two-way ANOVA was used for testing the effect of
prior associations in males and females.
Genotypic and phenotypic data of the present study is publicly
available through the NCBI dbGaP data repository: http://www.
ncbi.nlm.nih.gov/gap.
Table 3. Association of GDNF polymorphisms and mood dimensions.
Association analysis
dbSNP No alleles N MAF** Anxiety p Depression p
rs1981844 C 286 0.252 6.16 (63.87) 0.07491 3.04 (62.83) 0.02431
G 850 5.71 (63.41) 2.64 (62.53)
rs3812047 A 178 0.126 6.68 (63.72) 0.00070* 2.93 (62.55) 0.32941
G 1238 5.68 (63.50) 2.73 (62.55)
rs3096140 C 401 0.305 6.29 (63.48) 0.00138* 2.80 (62.51) 0.76512
T 915 5.59 (63.55) 2.75 (62.54)
rs2973041 G 224 0.162 5.64 (63.81) 0.52321 3.01 (62.81) 0.08250
A 1158 5.80 (63.50) 2.69 (62.51)
rs2910702 G 358 0.258 6.27 (63.62) 0.00356 2.83 (62.58) 0.59415
A 1030 5.60 (63.52) 2.74 (62.56)
rs1549250 G 593 0.423 6.07 (63.68) 0.01252 2.90 (62.67) 0.05343
T 809 5.56 (63.38) 2.63 (62.43)
rs2973050 T 410 0.352 6.11 (63.63) 0.05656 2.85 (62.69) 0.39771
C 756 5.65 (63.50) 2.72 (62.54)
rs11111 G 187 0.133 5.78 (63.86) 0.84093 2.97 (62.67) 0.22126
A 1223 5.79 (63.49) 2.72 (62.54)
Notes. *Significant after Bonferroni correction (p,0.00313) in single marker analyses. **MAF: minor allele frequency.
doi:10.1371/journal.pone.0080613.t003
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Results
Reliability of the tested phenotypes and genotypes
Chronbach Alpha values were calculated to test the internal
consistency of the self-report phenotypes. In the present sample
reliability coefficients were satisfactory for both Anxiety (0.75) and
Depression (0.68) scales. The Pearson’s correlation coefficient was
used to assess inter-correlation of the two scales: r = 0.54
(p,0.0001). Mean score of the anxiety scale was 5.80 (63.54),
with individual scores ranging from 0 to 19. Mean depression
score was 2.75 (62.55), with a range from 0 to 16. All
polymorphisms were in Hardy-Weinberg equilibrium [35] as the
p-values presented in Table 2 showed no significant differences
between the distribution of observed and calculated genotype
frequencies.
Age and sex as possible confounds
For testing sex differences on the two HADS scales Indepen-
dent-Samples t-test was applied. Females showed significantly
higher anxiety scores then males (6.47 compared to 5.02; t(706)
= –5.55; p,0.001), thus sex was used as a covariant in all
association analyses. Depression scores showed no significant sex
difference. There was no significant correlation between HADS
scales and age. This might be due to the relatively narrow age-
range in our sample, as 90% of participants were between
18–25 years of age.
Association analyses of mood characteristics and GDNF
polymorphisms
Table 3 summarizes results from the single marker analysis in
both mood dimensions using one-way ANCOVAs with one of the
GDNF SNPs as the grouping variable, with the HADS anxiety or
the depression scale as the dependent variable and with sex as
covariant. Association results for the 8 GDNF SNPs are
represented in each row with the number of detected alleles,
calculated MAF values, mean and standard deviation of anxiety
and depression scores for carriers of the presented alleles and the
corresponding p values from the ANCOVAs. Four SNPs
(rs3812047, rs3096140, rs2910702, rs1549250) were associated
with anxiety; scores were higher in the presence of the minor allele
in all four cases. Corresponding statistical values for the above four
SNPs labeled in bold in Table 3 were [F(1,1413) = 11.541,
p = 0.0007, g2= 0.008, power= 0.924]; [F(1,1313) = 10.282,
p = 0.00138, g2= 0.008, power= 0.893]; [F(1,1385) = 8.527,
p = 0.00356, g2= 0.006, power = 0.831]; and [F(1,1399) = 6.252,
p = 0.01252, g2=0.004, power = 0.705], respectively. One GDNF
SNP (rs1981844) showed association with the HADS depression
scale, with higher scores in the presence of the minor allele
[F(1,1133) = 5.086, p = 0.02431, g2=0.004, power = 0.615]. After
correction for multiple testing, association of anxiety with
rs3812047 and rs3096140 remained significant, labeled by single
stars in Table 3. Mean anxiety was significantly higher in the
presence of the minor (A) allele of the rs3812047 (6.6863.72) as
compared to the mean anxiety of major (G) allele carriers
(5.6863.50). The minor (C) allele of the rs3096140 was also a
genetic risk factor of anxiety, as mean scores in the presence of this
Figure 1. Linkage disequilibrium plots for the studied GDNF SNPs. A: Lewontin’s D’ measure and B: R2 values of linkage disequilibrium.
Higher values and darker squares indicate stronger pairwise linkage disequlibrium between two loci.
doi:10.1371/journal.pone.0080613.g001
Table 4. Haplotype analysis of risk alleles.
Haplotypes* N MAF** Anxiety p Depression p
rs3812047G_rs3096140T 853 0,602 5.49 (63.45) 0.00029 2.72 (62.60) 0.804
rs3812047G_rs3096140C 385 0,272 6.08 (63.57) 2.74 (62.46)
rs3812047A_rs3096140T 125 0,088 6.50 (64.04) 2.90 (62.53)
rs3812047A_rs3096140C 53 0,037 7.09 (62.80) 2.98 (62.64)
Notes. *Risk alleles in the haplotypes are labeled by bold. **MAF: minor allele frequency.
doi:10.1371/journal.pone.0080613.t004
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allele were higher (6.2963.48) as compared to those with the
major (T) allele (5.5963.55). Both GDNF SNPs explained 0.8% of
the variability of anxiety. Although the risk allele for anxiety was
the minor allele for both SNPs, the number of participants in the
study provided enough data points for association analyses with
sufficient power (for rs3812047 MAF=12.6%, N=178; for
rs3096140 MAF=30.5%, N=401).
Since the law enforcement subgroup of our sample showed
markedly lower anxiety mean scores than the subgroup of
psychology students and other volunteers, we carried out two
post-hoc analyses testing association of anxiety and the rs3812047
and rs3096140 GDNF polymorphisms without the law enforce-
ment subgroup. Omitting this subgroup did not alter our previous
findings using the total sample, the same pattern of risk alleles for
increased anxiety was demonstrated: Mean anxiety score was
higher (7.4363.56) in the presence of the rs3812047 A allele as
compared to 6.22(63.38) in those carrying the rs3812047 G allele
[F(1,903) = 12.358, p = 0.00046, g2=0.014, power = 0.940]. Sim-
ilarly, in the presence of the rs3096140 C allele mean anxiety level
was higher (6.7463.25) than in the presence of the rs3096140 T
allele (6.1763.50), [F(1,837) = 4.682, p = 0.03077, g2=0.006,
power = 0.580]. According to these results association of
rs3812047 and rs3096140 GDNF polymorphisms with anxiety
was consistent across participant subgroups.
Haplotype analysis
As the two SNPs (rs3812047 and rs3096140) significantly
associated with anxiety after correction for multiple testing were
not in linkage disequilibrium (D’ = 13, r2 = 0; see Figure 1A and
1B), haplotype analysis was also performed. One-way ANCOVAs
were applied on the two mood dimensions with the haploalleles as
the grouping variable and sex as covariant (results are presented in
Table 4). Effect of haplotypes on anxiety was significant
[F(1,1415) = 6.323, p= 0.00029, g2 = 0.013, power = 0.967], while
there was no significant differences in the mean scores of
depression. Mean anxiety was lowest when formerly defined risk
alleles were not present in the in the haplotype (5.4963.45). When
rs3096140C was present in the haploallele mean anxiety scores
were notably higher (6.0863.57). Anxiety scores were even higher
when rs3812047A was present in the haploallele (6.5064.04), and
anxiety reached its highest average in the presence of both risk
alleles in the haplotype (7.0962.80).
Effect of GDNF risk alleles on male and female anxiety
There was a significant sex difference in HADS anxiety scores.
In order to test if the significant genetic effects from our single
marker analyses were different for males and females we used two-
way ANOVAs on anxiety as the dependent variable and sex and
presence or absence of the risk allele of one of the two SNP as
grouping factors. Results are presented in Figure 2A and 2B. Main
effect of the rs3812047 SNP was significant [F(1,1412) = 13.391,
p = 0.0002, g2=0.009, power= 0.955] and as expected, we found
a significant main effect of sex [F(1,1412) = 12.48, p = 0.0004,
g2= 0.009, power= 0.942]. Interestingly a significant interaction
between sex and the rs3812047 SNP was also observed
[F(1,1412) = 4.539, p= 0.033, g2= 0.003, power = 0.567]. The
effect of the minor (A) allele as a risk for higher anxiety was more
pronounced in males as compared to females (Figure 2A).
Main effect of the rs3096140 SNP was also significant on
anxiety [F(1,1312) = 9.664, p = 0.002, g2= 0.007, power= 0.874],
and we also found a significant sex effect [F(1,1312) = 49.233,
p,0.0001, g2= 0.036, power = 1.000]. However, for this GDNF
SNP there was no significant gene-sex interaction. As presented in
Figure 2B both males and females with the minor (C) allele showed
higher anxiety.
Discussion
Evidence from twin studies confirms that mood characteristics
have a considerable genetic component. Heritability of major
depression is 37% [36,37] and heritability of affective and anxiety
disorders is around 45% [38]. The association between mood
disorders and the monoamine system, especially the dopamine
pathways, is well established [39–41], however, there are no prior
reports on the effect of GDNF polymorphisms on mood
characteristics in clinical or non-clinical populations.
Figure 2. Effect of GDNF risk alleles on male and female anxiety. Mean HADS anxiety scores in females and males as a function of rs3812047
(A) and rs3096140 (B) alleles. Open markers denote females; closed markers denote males. Error bars represent standard errors of the mean.
doi:10.1371/journal.pone.0080613.g002
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The aim of the present study was to investigate any possible
association of the GDNF gene polymorphisms with non-clinical
individual variations of anxiety and depression. Several methods
have been proposed to date for measuring mood characteristics
(for recent reviews see: [42,43]. In the present study we used the
HADS questionnaire which has been translated to several
languages [44] and is applicable to measure anxiety and
depression in somatic, psychiatric and non-clinical samples [45].
We also demonstrated applicability of the HADS questionnaire in
our previous genetic association findings, e.g. reporting association
between polymorphisms of the P2RX7 gene and depression scores
of diabetic patients [46] and patients with major depression or
bipolar disorder [47].
Here we explored the association of 8 GDNF polymorphisms
with anxiety and depression (Table 3). After correcting for multiple
testing, the genetic effect on depression did not remain significant;
however, two of the studied GDNF SNPs (rs3812047A and
rs3096140C) were identified as possible risk alleles of anxiety (level
of significance for the two associations were p= 0.00070 and
0.00138, respectively). We replicated these association findings
using a subsample without the law enforcement subgroup, since
they showed markedly lower anxiety mean scores than the
subgroup of psychology students and other volunteers. Mean
anxiety scores were higher in the presence of the rs3812047 A and
the rs3096140 C risk alleles. According to these results association
of rs3812047 and rs3096140 GDNF polymorphisms with anxiety
was consistent across participant subgroups.
Since the two risk-SNPs were not in linkage disequilibrium we
also performed haplotype analysis of these SNPs. Results described
in Table 4 underlie the significant genetic effect indicated by our
single-marker analyses: mean anxiety scores raised according to
the number of risk alleles present in the haplotypes (p = 0.00029).
It should be noted that anxiety and depression scales of the HADS
questionnaire correlate (r = 0.54, p,0.0001) implicating that these
two constructs are in close relation. One possible reason for the
lack of significant effects of GDNF polymorphisms on depression in
the present study is that depression scores were quite low in our
non-clinical sample. This floor effect [48] might have reduced
individual variation, and diminished genetic effects.
Findings from previous studies also confirm sex differences in
anxiety. Higher anxiety of females was consistent according to a
meta-analysis [49] with studies using a wide range of subject pool
and anxiety measures (e.g. State-Trait Anxiety Inventory, Chil-
dren’s Manifest Anxiety Scale, Minnesota Multiphasic Personality
Inventory). Anxiety disorders are also more frequent in females
and more anxiety symptoms characterize them [50]. Neurotrans-
Figure 3. A. Localization of the analyzed human GDNF gene polymorphisms. Exons are labeled by filled boxes, the approximate position of
the studied SNPs by filled triangles. SNPs showing significant association with anxiety after correction for multiple testing are in bold. ATG 1,2,3 and 4:
alternative start sites, TGA: stop signal. B. Fine map of the genomic location of GDNF isoforms. Chromosomal positions of exons in each
transcription variant are indicated at the bottom. (Please note, that introns are longer than they appear in the figure.) Arrows pointing up indicate the
start and stop codons of open reading frames in each isoform. Chromosomal localization of rs3812047 and rs3096140 are shown on the top. Distance
between exon 1 of variant 2 and rs3812047 is 99 bp, whereas exon 2 is 474 bp away from the polymorphic locus. Similarly, distance between exon 2
of isoform 1 or 3 and rs3096140 is 1915 bp, and exon 3 is 16596 bp away from the SNP.
doi:10.1371/journal.pone.0080613.g003
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mitter systems probably play an important role in the background
of these differences [51], for example through the estrogen system
increasing monoamine synthesis (dopamine, serotonin, norepi-
nephrine) and receptor sensitivity [52]. Our results support these
findings, as female subjects reported higher anxiety scores.
However, we also report an interaction effect of sex and
rs3812047 SNP on anxiety (Figure 2A). Males with the minor
(A) allele showed anxiety scores as high as females with the major
(G) allele of this polymorphism. Females with the risk (A) allele
reported even higher anxiety scores. Others [53] also reported
interaction effect of sex and the BDNF Val66Met polymorphism
on stress reactivity.
Limitations of the presented study involve the relatively low
sample size, therefore the possibility of false positive findings could
not be excluded despite the fact that the two reported significant
findings survived the Bonferroni-correction for multiple testing.
Therefore further replications with independent samples are
necessary. Moreover, no functional data are available concerning
the intronic SNPs shown here to associate with anxiety, however,
it is important to note that both anxiety-linked SNPs are in the
close proximity of critical sites of alternative splicing (Figure 3.A.
and B). Nevertheless, the fact that only these two SNPs associate
firmly with anxiety might imply their significance in the control of
gene expression. As far as the molecular background of this novel
association is concerned, it is tempting to assume that these
polymorphisms might be involved in the regulation of alternative
splicing of the GDNF gene. Importantly, there are two main types
of alternatively spliced preproGDNF isoforms, alpha and beta, the
latter possessing a significantly shorter propeptide sequence due to
the presence of an alternative splicing site in exon 3 of the gene
[54], resulting in four isoforms as shown on Figure 3 B. Although
the functional differences of GDNF variants are not fully
understood, altered processing and secretion of the protein
isoforms have been demonstrated [55]. This assumption seems
highly probable in the light of recent publications assigning a
pivotal role to intronic polymorphisms in governing splicing
processes via differential recruitment of key splicing factors. For
instance, two intronic SNPs in the type 2 dopamine receptor gene
(DRD2) have been found sufficient to affect alternative splicing
and therefore susceptibility to cocaine abuse [56]. Similar
interactions between intronic SNPs and alternatively spliced
isoforms have also been described in case of the human myocilin
[57] and insulin [58] as well as the human papilloma virus E6/E7
genes [59], just to mention but a few.
Albeit several lines of biochemical evidence argue for the role of
GDNF in dopaminergic differentiation [1], relatively scarce and
ambiguous data have been gained from association studies with
regard to its involvement in the pathogenesis of neuropsychiatric
disorders. To date, a cohort of association analyses has suggested
that certain GDNF polymorphisms might be linked to schizophre-
nia, a pervasive neurodevelopmental disorder [20,23]. Recent
findings from Ahmadiantehrani and Ron [60] seem to corroborate
these results by revealing that upregulated DRD2 signaling, a
hallmark of schizophrenia, resulted in elevated GDNF expression
levels.
To our best knowledge, this is the first report shedding light on
the significance of the rs3812047 and rs3096140 SNPs that have
not been found to significantly associate with any known traits or
disorders before. Previously, a study conducted on Japanese drug
abusers identified a GDNF SNP associated with metamphetamine
dependence [27]. It is widely known that anxiety disorders such as
generalized anxiety disorder, phobias, panic- and compulsivity
disorders are often accompanied by drug addiction, smoking and
heavy drinking [61,62]. In light of results presented here, GDNF
might be one of the common factors that links anxiety to substance
abuse.
This is the first report on association between anxiety and the
polymorphisms of GDNF gene; however, since we used a non-
clinical sample we could assess genetic background of individual
variation in anxiety below the clinical threshold. Further studies
are needed to reveal whether the genetic risk factors suggested
here are related to higher vulnerability of mood disorders.
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